Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com
IKZF1 Deletions Predict Poor Prognosis in Pediatric ALL
March 7th 2018IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL.
Read More
Blood Test May Predict Palbociclib Response Earlier in Breast Cancer
March 2nd 2018A blood test that detects early changes in circulating tumor DNA may provide an earlier indication of whether patients with hormone receptor–positive, HER2-negative breast cancer are responding to palbociclib (Ibrance).
Read More
European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer
February 23rd 2018European regulators have recommended against approving a marketing authorization application for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.
Read More
Liquid Biopsy Demonstrates Prognostic Potential in Metastatic TNBC
February 21st 2018Low-coverage genome-wide sequencing of cell-free DNA from plasma is capable of profiling cancer genomes from blood and predicting survival outcomes for patients with metastatic triple-negative breast cancer.
Read More
Lenvatinib HCC Data Published as FDA Considers Approval
February 20th 2018Lenvatinib (Lenvima) was noninferior for overall survival while improving progression-free survival compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma.
Read More
Concomitant Chemoradiation Remains Standard in Locally Advanced Cervical Cancer
February 19th 2018Standard cisplatin-based concomitant chemoradiation induced superior disease-free survival compared with neoadjuvant chemotherapy followed by radical surgery in women with locally advanced squamous cervical cancer.
Read More
Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma
February 17th 2018Investigators with the FDA’s Center for Drug Evaluation and Research and Oncology Center of Excellence conducted a pooled analysis of all trial reports and data marketing applications for the use of anti–PD-1 antibodies alone or in combination to treat patients with unresectable or metastatic melanoma.
Read More
FDA Panel to Review Blinatumomab Application for MRD-positive ALL
February 16th 2018The FDA's Oncologic Drugs Advisory Committee is slated to review a supplemental biologics license application for the use of blinatumomab for the treatment of patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.
Read More
Robotic Radiosurgery May Provide New Option for Recurrent Gynecologic Cancers
February 9th 2018The administration of stereotactic body radiation therapy through the use of CyberKnife therapy appears to be a safe and effective salvage treatment for women with previously irradiated, locally recurrent gynecologic cancer.
Read More
Study Highlights Impact of Race, Geography on Genetic Variation in Endometrial Cancer
February 9th 2018An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer.
Read More